Details for: FRAXIPARINE
Company: ASPEN PHARMACARE CANADA INC.
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02236913 | FRAXIPARINE | NADROPARIN CALCIUM | 9500 UNIT / ML | SOLUTION | INTRAVENOUS |
| 02450623 | FRAXIPARINE | NADROPARIN CALCIUM | 9500 UNIT / ML | SOLUTION | INTRAVENOUS |
| 02450631 | FRAXIPARINE | NADROPARIN CALCIUM | 9500 UNIT / ML | SOLUTION | INTRAVENOUS |
| 02450658 | FRAXIPARINE | NADROPARIN CALCIUM | 9500 UNIT / ML | SOLUTION | INTRAVENOUS |
| 02236913 | FRAXIPARINE | NADROPARIN CALCIUM | 9500 UNIT / ML | SOLUTION | SUBCUTANEOUS |
| 02450623 | FRAXIPARINE | NADROPARIN CALCIUM | 9500 UNIT / ML | SOLUTION | SUBCUTANEOUS |
| 02450631 | FRAXIPARINE | NADROPARIN CALCIUM | 9500 UNIT / ML | SOLUTION | SUBCUTANEOUS |
| 02450658 | FRAXIPARINE | NADROPARIN CALCIUM | 9500 UNIT / ML | SOLUTION | SUBCUTANEOUS |
Summary Reports
Regulatory Decision Summary
Summary Safety Review - Low-Molecular-Weight Heparins - Assessing the potential risk of bleeding in or around the spinal cord (Spinal/Epidural Hematoma)
Summary Safety Review - Low-Molecular-Weight Heparins - Assessing the potential risk of bleeding in or around the spinal cord (Spinal/Epidural Hematoma)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.